[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-331742-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-331742-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploring-the-clinical-utility-of-liquid-biopsy-with-cfdna-in-cancer-a-systematic-review","Exploring the clinical utility of liquid biopsy with cfDNA in cancer - A systematic review","","Various tumor cells may exhibit distinct genetic and phenotypic features, a driver of metastasis and tumor heterogeneity that can limit information from accessible biopsies for treatment decisions. Liquid biopsy analyzes metastatic DNA signals in biofluids, primarily cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA). Studies evaluate cfDNA/ctDNA as diagnostic, prognostic, and monitoring biomarkers, including minimal residual disease (MRD) to reflect treatment response, relapse, and emergence of therapy resistance. This review summarizes recent evidence and the clinical relevance in routine cancer practice in India.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-the-clinical-utility-of-liquid-biopsy-with-cfdna-in-cancer-a-systematic-review/331742/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-the-clinical-utility-of-liquid-biopsy-with-cfdna-in-cancer-a-systematic-review/331742.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does tumor heterogeneity create for traditional biopsies?","Question",{"text":63,"@type":64},"Tumor heterogeneity can produce multiple molecular subtypes within one patient via metastases. Biopsying an easily accessible metastasis may not capture the full tumor characteristics needed for treatment decisions.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does liquid biopsy use cfDNA/ctDNA to support cancer care?",{"text":68,"@type":64},"Liquid biopsy probes metastatic deposits using biofluids such as peripheral blood. It analyzes cfDNA/ctDNA to provide insights into therapeutic targets and gene alterations related to treatment resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"What is minimal residual disease (MRD) in the context of cfDNA/ctDNA?",{"text":72,"@type":64},"MRD detection uses cfDNA/ctDNA signals to indicate remaining cancer after treatment. It provides information on the efficiency of the treatment regimen and whether cancer cells have developed resistance to a specific regimen.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},331742,1790097624,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","The Journal of Liquid Biopsy 5 (2024) 100150  \nContents lists available at ScienceDirect  \nThe Journal of Liquid Biopsy  \njournal [homepage:](homepage: www.sciencedirect.com/journal/the-journal-of-liquid-biopsy)[ www.sciencedirect.com/journal/the-journal-of-liquid-biopsy](homepage: www.sciencedirect.com/journal/the-journal-of-liquid-biopsy)  \nExploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review  \nKeerthi Ranganathan 1, Neethu Sheri Kurian 1, Hitesh M. Goswami, Kshitij D. Rishi,  \n*  \nVidya H. Veldore  \n4baseCare, BHIVE Workspace Whitefield, 8th Floor, Whitefield Main Rd, Brigade Metropolis, Garudachar Palya, Mahadevapura, Bengaluru, Karnataka, 560048, India  \n\n| A R T I C L E I N F O |  | A B S T R A C T |\n| --- | --- | --- |\n| Keywords: Tumor\u003Cbr>Tumor heterogeneity Liquid biopsy\u003Cbr>Cell-free DNA (cfDNA)\u003Cbr>Circulating tumor DNA (ctDNA) Minimal residual disease (MRD) Clinical utility |  | Various tumor cells may exhibit different genetic or phenotypic characteristics. This phenomenon of cancer cells, known as Tumor Heterogeneity, is responsible for multiple cancer sites caused in a single patient through metastases. It is possible that the biopsy of the most accessible metastasis will not provide enough information toreexamine tumor features and make therapeutic recommendations. Liquid biopsy is a diagnostic technique that probes metastatic deposits from biofluids like peripheral blood for cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) from cancer patients. This analysis provides researchers and oncologists a comprehensive insight into therapeutic targets and treatment resistance-causing gene alterations.\u003Cbr>Various studies have validated that cfDNA/ctDNA may be essential in tumor analysis, constituting the need for the identification of cancer cells that may reactivate and proliferate, causing the disease to reoccur. This detection is also called Minimal Residual Disease (MRD) and shares insights on the efficiency of the treatment regimen and if the cancer cells have developed resistance to a specific treatment regimen.\u003Cbr>In this review, the significance of cfDNA/ctDNA as a possible diagnostic, prognostic, or monitoring biomarker for solid tumors has been evaluated in recent studies, and its clinical relevance in routine cancer clinics in India has been reviewed. |\n\n1. Introduction  \nIn the past ten years, liquid biopsy has become a cutting-edge, minimally invasive, and potential method capable of delivering crucial information about the molecular characteristics of solid tumors. Cell-free DNA (cfDNA) was first encountered in 1948 and garnered interest despite its initial insignificance. Its clinical significance became evident as distinctions in cfDNA characteristics between normal individuals and cancer patients emerged. The first occurrence of high levels of cfDNA was observed in Leukemia and autoimmune disease patients. Decades of further research have consistently shown that high levels of cfDNA are generally associated with cancer patients. A noteworthy observation was demonstrated by Stroun and associates in 1989 that tumor cells released plasma cfDNA. Subsequent studies verified that cancerous cells release identifiable cfDNA fragments into the bloodstream. Additionally, it was shown that these segments had distinct epigenetic and genetic variants compared to the original tumor [1].  \nAlthough a lot of research has been done on the utility of liquid biopsy to clarify the molecular features of cancers of the Lung, Colon, Rectum, Breast, Ovaries, Pancreas, Prostate, and Lymphatic system, its application to other cancer types is still largely unexplored. This phenomenon could stem some inherent aspects of the disease, such as tumor heterogeneity, which can give rise to multiple cancer molecular subtypes within a single patient through metastasis. Consequently, reassessing tumor characteristics based solely on biopsies from easily accessible metastases may yield insufficient information for tr","cbCaiezODoZ1G2Lm","https://ap.wps.com/l/cbCaiezODoZ1G2Lm","pdf",1053114,13,"English","# Introduction\n# Liquid biopsy: an evolving paradigm in solid tumor management","[{\"question\":\"What problem does tumor heterogeneity create for traditional biopsies?\",\"answer\":\"Tumor heterogeneity can produce multiple molecular subtypes within one patient via metastases. Biopsying an easily accessible metastasis may not capture the full tumor characteristics needed for treatment decisions.\"},{\"question\":\"How does liquid biopsy use cfDNA/ctDNA to support cancer care?\",\"answer\":\"Liquid biopsy probes metastatic deposits using biofluids such as peripheral blood. It analyzes cfDNA/ctDNA to provide insights into therapeutic targets and gene alterations related to treatment resistance.\"},{\"question\":\"What is minimal residual disease (MRD) in the context of cfDNA/ctDNA?\",\"answer\":\"MRD detection uses cfDNA/ctDNA signals to indicate remaining cancer after treatment. It provides information on the efficiency of the treatment regimen and whether cancer cells have developed resistance to a specific regimen.\"}]","Exploring the clinical utility of liquid biopsy with cfDNA in cancer - A systematic review | PDF",1789994956,33]